Key Highlights
- 6.34% is the indicated pre-market move for Quantum Cyber N.V. (NASDAQ:QUCY) on November 17, 2026, taking the indicated price to USD 0.6221 from a calculated prior close of USD 0.5850.
- 13.4 million is the USD cash balance reported at June 30, 2026, up from USD 0.9 million at year end 2025, following Equity and Warrant financing during the first half of 2026.
- 11.0 million was the USD net loss from continuing operations in the second quarter of 2026 versus USD 3.5 million a year earlier, with no Revenue from continuing operations.
- 250 million is the USD size of a planned registration to raise Capital for AI and quantum driven autonomous platforms, far above current cash and a signal of potential dilution.
What Moved Quantum Cyber N.V. (NASDAQ:QUCY) in Pre-Market Trading on November 17, 2026 (+USD 0.0371, +6.34%)
The indicated pre-market price on November 17, 2026 is USD 0.6221, a pre-market move of +6.34%. On a calculated basis, the prior close was USD 0.5850 (price divided by 1.0634) and the USD move is +USD 0.0371 (price minus prior close). The indicated price is below USD 1.00. No pre-market Volume or Liquidity figures were found in published coverage. The company, formerly Mainz Biomed N.V. and based in Mainz, Germany, moved from in vitro diagnostics to AI and quantum enabled autonomous systems focused on drones and defense.
The Rationale: No Identified Catalyst, Drone Pivot Backdrop for Quantum Cyber N.V. (NASDAQ:QUCY)
No company-specific catalyst for the move was identified in published coverage, so what follows is general context. Small-cap drone, defense and quantum stocks often trade on sector sentiment, which thin pre-market order books can magnify. The company sold its colorectal cancer screening business, rebranded as Quantum Cyber, launched a Quantum Drones segment and secured technology licenses and Manufacturing assets. In June 2026 it outlined plans for an advanced filament manufacturing division for defense applications. Management said it expects current cash plus new financing to cover planned spending for at least one year, and it plans to invest in research, development and manufacturing.
Valuation, Liquidity and Risks for Quantum Cyber N.V. (NASDAQ:QUCY)
A corroborated market Capitalization and share count were not found. In the second half of 2025 the company reported a 40% revenue decline and a USD 16.2 million net loss, and its first half 2026 report was published on August 14, 2026. For the six months ended June 30, 2026, net loss from continuing operations was USD 16.1 million versus USD 8.5 million, and operating expenses were USD 12.4 million, with USD 9.9 million in the second quarter. Cash of USD 13.4 million compares with second quarter operating expenses of USD 9.9 million, so further financing is likely. Filings show offerings of up to 4.59 million shares and units with Maxim Group LLC as Placement agent, plus a planned USD 250 million registration, so dilution is a central risk. Execution risk, no revenue and a sub-USD 1.00 share price add to the risk profile.
Where Things Stand
Quantum Cyber (NASDAQ:QUCY) is indicated at USD 0.6221 in pre-market trading on November 17, 2026, up +6.34% from a calculated prior close of USD 0.5850, with no identified catalyst. The company has transformed from a diagnostics Business into a drone and defense technology developer, reporting no continuing revenue, a USD 16.1 million six month net loss and USD 13.4 million of cash at June 30, 2026. With a USD 250 million registration planned and offerings through Maxim Group LLC on file, financing and dilution remain the central questions as 13 employees attempt to execute a new strategy.






Please wait processing your request...